3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
18
Phase 1
15
Phase 1/2
5
Phase NA
4
Phase 3
3
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Tuberous Sclerosis
2
Autistic Disorder
2
Uterine Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Intellectual Disability
1
Hamartoma Syndrome, Multiple
1
Gastroenteropancreatic Neuroendocrine Tumors
1
Gallbladder Neoplasms
1
Adenoma, Islet Cell
1
Interventions
Gemcitabine
5
Capecitabine
4
pembrolizumab
3
Fluorouracil
3
Cisplatin
3
vinflunine
2
enzalutamide
2
cabazitaxel
2
abiraterone
2
Ipilimumab
2
Haloperidol
2
Androgen Antagonists
2
vedolizumab
1
trifluridine tipiracil drug combination
1
relugolix
1
racemetyrosine
1
nimotuzumab
1
nilutamide
1
lanreotide
1
histrelin
1
futibatinib
1
exemestane
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
bicalutamide
1
beta-Glucans
1
auricularum
1
atezolizumab
1
apatinib
1
apalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Neoplasm Metastasis
×
Everolimus
×
Clear all
NCT06943755
2026-04-17
STELLAR-311
Exelixis
Phase 2/3
Recruiting
440 enrolled